aspartic acid has been researched along with Colorectal Neoplasms in 48 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to investigate whether N-(phosphonacetyl)-L-aspartic acid (PALA) can enhance the activity of low-dose methotrexate (LD-MTX) modulated infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer." | 9.10 | High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group. ( Baron, B; Bleiberg, H; Blijham, GH; Couvreur, ML; De Greve, J; Genicot, B; Jansen, RL; Kok, TC; Nortier, JW; Wagener, T; Wils, J, 2003) |
| "To report a new syndrome of ascites, hyperbilirubinemia, and hypoalbuminemia after treatment with N-phosphonacetyl-L-aspartate (PALA) and fluorouracil for metastatic colorectal cancer." | 9.07 | A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA) ( Costa, P; Kemeny, N; Kurtz, RC; Martin, D; Murray, M; Niedzwiecki, D; Seiter, K; Urmacher, C, 1991) |
| "A novel sequential administration schedule of PALA (N-phosphonoacetyl-L-aspartate) and thymidine to enhance the cytotoxic effect of 5-fluorouracil (5FU) was tested in 36 patients with advanced gastric cancer and 21 patients with advanced poorly differentiated (anaplastic) colorectal cancer." | 9.06 | A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer. ( Goldberg, RM; Krook, JE; Kugler, JW; Laurie, JA; Moertel, CG; O'Connell, MJ; Pfeifle, DM; Rubin, J; Wieand, HS; Windschitl, HE, 1990) |
| "5-Fluorouracil (5-FU) remains the agent of choice for the treatment of colorectal cancer." | 8.80 | Biomodulation of Fluorouracil in colorectal cancer. ( Ardalan, B; Franceschi, D; Jaime, M; Luis, R, 1998) |
| "The aim of this study was to investigate the utility of quantitating thymidylate synthase (TS) in the primary tumor as a surrogate for metastatic disease sites to predict the likelihood of response and outcome to fluorouracil (FU) treatment in patients with metastatic colorectal cancer." | 7.72 | Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. ( Allegra, CJ; Benson, AB; Catalano, P; Johnston, PG; O'Dwyer, PJ; Rao, MS, 2003) |
| "Higher response rates in colorectal cancer have been observed with regimens that increase the cytotoxicity of fluorouracil (5-FU) by altering the biochemical milieu at its site(s) of action." | 7.68 | Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. ( Comis, RL; Litwin, S; O'Dwyer, PJ; Paul, AR; Walczak, J; Weiner, LM, 1990) |
| "The treatment of metastatic colorectal cancer by chemotherapy alone was considered palliative and without the potential to cure patients unless patients were rendered resectable." | 5.33 | Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases. ( Kemeny, NE; Leonard, GD, 2006) |
| "The aim of this study was to investigate whether N-(phosphonacetyl)-L-aspartic acid (PALA) can enhance the activity of low-dose methotrexate (LD-MTX) modulated infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer." | 5.10 | High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group. ( Baron, B; Bleiberg, H; Blijham, GH; Couvreur, ML; De Greve, J; Genicot, B; Jansen, RL; Kok, TC; Nortier, JW; Wagener, T; Wils, J, 2003) |
| "To report a new syndrome of ascites, hyperbilirubinemia, and hypoalbuminemia after treatment with N-phosphonacetyl-L-aspartate (PALA) and fluorouracil for metastatic colorectal cancer." | 5.07 | A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA) ( Costa, P; Kemeny, N; Kurtz, RC; Martin, D; Murray, M; Niedzwiecki, D; Seiter, K; Urmacher, C, 1991) |
| "A novel sequential administration schedule of PALA (N-phosphonoacetyl-L-aspartate) and thymidine to enhance the cytotoxic effect of 5-fluorouracil (5FU) was tested in 36 patients with advanced gastric cancer and 21 patients with advanced poorly differentiated (anaplastic) colorectal cancer." | 5.06 | A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer. ( Goldberg, RM; Krook, JE; Kugler, JW; Laurie, JA; Moertel, CG; O'Connell, MJ; Pfeifle, DM; Rubin, J; Wieand, HS; Windschitl, HE, 1990) |
| "5-Fluorouracil (5-FU) remains the agent of choice for the treatment of colorectal cancer." | 4.80 | Biomodulation of Fluorouracil in colorectal cancer. ( Ardalan, B; Franceschi, D; Jaime, M; Luis, R, 1998) |
| "For nearly four decades, 5-fluorouracil (5-FU) has been the mainstay of treatment for colorectal cancer." | 4.80 | Where do we stand with 5-fluorouracil? ( Büchele, T; Dempke, W; Grothey, A; Schmoll, HJ, 1999) |
| "5-Fluorouracil (5-FU) is still the mainstay of chemotherapy in patients with metastatic colorectal cancer." | 4.78 | Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials. ( Harstrick, A; Köhne-Wömpner, CH; Rustum, YM; Schmoll, HJ, 1992) |
| "The aim of this study was to investigate the utility of quantitating thymidylate synthase (TS) in the primary tumor as a surrogate for metastatic disease sites to predict the likelihood of response and outcome to fluorouracil (FU) treatment in patients with metastatic colorectal cancer." | 3.72 | Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. ( Allegra, CJ; Benson, AB; Catalano, P; Johnston, PG; O'Dwyer, PJ; Rao, MS, 2003) |
| "Higher response rates in colorectal cancer have been observed with regimens that increase the cytotoxicity of fluorouracil (5-FU) by altering the biochemical milieu at its site(s) of action." | 3.68 | Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. ( Comis, RL; Litwin, S; O'Dwyer, PJ; Paul, AR; Walczak, J; Weiner, LM, 1990) |
| " Low dose and either continuous infusion or repetitive dosing of leucovorin, as well as the effect of treatment sequence and intervals between drugs, require additional investigation." | 2.39 | Preclinical and clinical aspects of biomodulation of 5-fluorouracil. ( Allegra, CJ; Grogan, L; Sotos, GA, 1994) |
| "The treatment of advanced colorectal cancer has improved in recent years." | 2.38 | Recent advances in the treatment of advanced colorectal cancer. ( Ahlgren, JD; Anderson, N; Kemeny, N; Lokich, JJ, 1993) |
| "Many colorectal cancer (CRC) cells contain mutations in KRAS." | 1.43 | SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate. ( Cai, Z; Chen, H; Cheng, KW; Go, MY; Jin, Y; Kang, W; Li, W; Li, X; Ng, SS; Qian, Y; Sung, JJ; To, KF; Tong, JH; Wong, CC; Wu, JL; Xu, J; Yu, J, 2016) |
| "To improve the quality of life of colorectal cancer patients, it is important to establish new screening methods for early diagnosis of colorectal cancer." | 1.38 | A novel serum metabolomics-based diagnostic approach for colorectal cancer. ( Azuma, T; Hayashi, N; Ikeda, A; Izumi, Y; Kawano, S; Kibi, M; Kobayashi, T; Nishiumi, S; Okuno, T; Takenawa, T; Yoshida, M; Yoshie, T, 2012) |
| "The treatment of metastatic colorectal cancer by chemotherapy alone was considered palliative and without the potential to cure patients unless patients were rendered resectable." | 1.33 | Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases. ( Kemeny, NE; Leonard, GD, 2006) |
| "The increased risk of colorectal cancer in biallelic and monoallelic MYH gene mutation carriers was not consistently associated with the development of multiple adenomatous polyps." | 1.32 | Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. ( Aronson, M; Cleary, SP; Cotterchio, M; Croitoru, ME; Di Nicola, N; Gallinger, S; Gryfe, R; Knight, J; Manno, M; Redston, M; Selander, T, 2004) |
| "Once positive the circulating tumor cells persisted in subsequent multiple blood samples." | 1.31 | K-ras mutational analysis of polyclonal colorectal cancers identifies uniclonal circulating tumor cells. ( Krygier, S; Luchtefeld, MA; Senagore, AJ; Thebo, JS, 2001) |
| "Twenty-one paired pharmacokinetic studies were completed on patients with colorectal, gastric, and hepatocellular cancer, utilizing positron emission tomography (PET), which allowed the acquisition of tumor, normal tissue, and plasma pharmacokinetic data and tumor blood flow (TBF) measurements." | 1.30 | Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa. ( Brady, F; Brown, G; Harte, RJ; Jones, T; Luthra, SJ; Matthews, JC; O'Reilly, SM; Osman, S; Price, PM; Tilsley, DW, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.08) | 18.7374 |
| 1990's | 25 (52.08) | 18.2507 |
| 2000's | 15 (31.25) | 29.6817 |
| 2010's | 6 (12.50) | 24.3611 |
| 2020's | 1 (2.08) | 2.80 |
| Authors | Studies |
|---|---|
| Doubleday, PF | 1 |
| Fornelli, L | 1 |
| Ntai, I | 1 |
| Kelleher, NL | 1 |
| Mazurenko, NN | 1 |
| Gagarin, IM | 1 |
| Tsyganova, IV | 1 |
| Mochal'nikova, VV | 1 |
| Breder, VV | 1 |
| Pedraz-Cuesta, E | 1 |
| Christensen, S | 1 |
| Jensen, AA | 1 |
| Jensen, NF | 1 |
| Bunch, L | 1 |
| Romer, MU | 1 |
| Brünner, N | 1 |
| Stenvang, J | 1 |
| Pedersen, SF | 1 |
| Wong, CC | 1 |
| Qian, Y | 1 |
| Li, X | 1 |
| Xu, J | 1 |
| Kang, W | 1 |
| Tong, JH | 1 |
| To, KF | 1 |
| Jin, Y | 1 |
| Li, W | 1 |
| Chen, H | 1 |
| Go, MY | 1 |
| Wu, JL | 1 |
| Cheng, KW | 1 |
| Ng, SS | 1 |
| Sung, JJ | 1 |
| Cai, Z | 1 |
| Yu, J | 1 |
| Kasahara, M | 1 |
| Osawa, K | 1 |
| Yoshida, K | 1 |
| Miyaishi, A | 1 |
| Osawa, Y | 1 |
| Inoue, N | 1 |
| Tsutou, A | 1 |
| Tabuchi, Y | 1 |
| Tanaka, K | 1 |
| Yamamoto, M | 1 |
| Shimada, E | 1 |
| Takahashi, J | 1 |
| Normanno, N | 1 |
| Tejpar, S | 1 |
| Morgillo, F | 1 |
| De Luca, A | 1 |
| Van Cutsem, E | 1 |
| Ciardiello, F | 1 |
| Panda, H | 1 |
| Jaiswal, AS | 1 |
| Corsino, PE | 1 |
| Armas, ML | 1 |
| Law, BK | 1 |
| Narayan, S | 1 |
| Zulhabri, O | 1 |
| Rahman, J | 1 |
| Ismail, S | 1 |
| Isa, MR | 1 |
| Wan Zurinah, WN | 1 |
| Nishiumi, S | 1 |
| Kobayashi, T | 1 |
| Ikeda, A | 1 |
| Yoshie, T | 1 |
| Kibi, M | 1 |
| Izumi, Y | 1 |
| Okuno, T | 1 |
| Hayashi, N | 1 |
| Kawano, S | 1 |
| Takenawa, T | 1 |
| Azuma, T | 1 |
| Yoshida, M | 1 |
| Mao, C | 1 |
| Huang, YF | 1 |
| Yang, ZY | 1 |
| Zheng, DY | 1 |
| Chen, JZ | 1 |
| Tang, JL | 1 |
| Wils, J | 1 |
| Blijham, GH | 1 |
| Wagener, T | 1 |
| De Greve, J | 1 |
| Jansen, RL | 1 |
| Kok, TC | 1 |
| Nortier, JW | 1 |
| Bleiberg, H | 1 |
| Couvreur, ML | 1 |
| Genicot, B | 1 |
| Baron, B | 1 |
| Johnston, PG | 1 |
| Benson, AB | 2 |
| Catalano, P | 1 |
| Rao, MS | 1 |
| O'Dwyer, PJ | 7 |
| Allegra, CJ | 2 |
| Hwang, YH | 1 |
| Suh, CK | 1 |
| Park, SP | 1 |
| Gismondi, V | 1 |
| Meta, M | 1 |
| Bonelli, L | 1 |
| Radice, P | 1 |
| Sala, P | 1 |
| Bertario, L | 1 |
| Viel, A | 1 |
| Fornasarig, M | 1 |
| Arrigoni, A | 1 |
| Gentile, M | 1 |
| Ponz de Leon, M | 1 |
| Anselmi, L | 1 |
| Mareni, C | 1 |
| Bruzzi, P | 1 |
| Varesco, L | 1 |
| Whitehead, RP | 1 |
| Benedetti, JK | 1 |
| Abbruzzese, JL | 1 |
| Ardalan, B | 3 |
| Williamson, S | 1 |
| Gaynor, ER | 1 |
| Balcerzak, SP | 1 |
| Macdonald, JS | 1 |
| Croitoru, ME | 1 |
| Cleary, SP | 1 |
| Di Nicola, N | 1 |
| Manno, M | 1 |
| Selander, T | 1 |
| Aronson, M | 1 |
| Redston, M | 1 |
| Cotterchio, M | 1 |
| Knight, J | 1 |
| Gryfe, R | 1 |
| Gallinger, S | 1 |
| Leonard, GD | 1 |
| Kemeny, NE | 1 |
| Suzuki, A | 1 |
| Ogura, T | 1 |
| Esumi, H | 1 |
| Sotos, GA | 1 |
| Grogan, L | 1 |
| Meropol, NJ | 1 |
| Creaven, PJ | 1 |
| Petrelli, NJ | 1 |
| Leichman, CG | 1 |
| Fleming, TR | 1 |
| Muggia, FM | 1 |
| Tangen, CM | 1 |
| Doroshow, JH | 1 |
| Meyers, FJ | 1 |
| Holcombe, RF | 1 |
| Weiss, GR | 1 |
| Mangalik, A | 1 |
| Fossum, B | 1 |
| Gedde-Dahl, T | 1 |
| Breivik, J | 1 |
| Eriksen, JA | 1 |
| Spurkland, A | 1 |
| Thorsby, E | 1 |
| Gaudernack, G | 1 |
| Cao, S | 1 |
| Rustum, YM | 2 |
| Spector, T | 1 |
| Kemeny, N | 4 |
| Lokich, JJ | 1 |
| Anderson, N | 1 |
| Ahlgren, JD | 1 |
| Weiner, LM | 3 |
| Hudes, GR | 2 |
| Kitson, J | 1 |
| Walczak, J | 2 |
| Watts, P | 1 |
| Litwin, S | 2 |
| Ragnhammar, P | 1 |
| Blomgren, H | 1 |
| Hageboutros, A | 1 |
| Greene, F | 1 |
| LaCreta, FP | 1 |
| Brennan, J | 1 |
| Köhne, CH | 2 |
| Wilke, H | 2 |
| Schöffski, P | 2 |
| Schmoll, HJ | 4 |
| Harstrick, A | 2 |
| Hiddemann, W | 1 |
| Bokemeyer, C | 1 |
| Dörken, B | 1 |
| Luis, R | 1 |
| Jaime, M | 1 |
| Franceschi, D | 1 |
| Soulie, P | 1 |
| Poupon, MF | 1 |
| Remvikos, Y | 1 |
| Dutrillaux, B | 1 |
| Muleris, M | 1 |
| Harte, RJ | 1 |
| Matthews, JC | 1 |
| O'Reilly, SM | 1 |
| Tilsley, DW | 1 |
| Osman, S | 1 |
| Brown, G | 1 |
| Luthra, SJ | 1 |
| Brady, F | 1 |
| Jones, T | 1 |
| Price, PM | 1 |
| Royce, ME | 1 |
| McGarry, W | 1 |
| Bready, B | 1 |
| Dakhil, SR | 1 |
| Belt, RJ | 1 |
| Goodwin, JW | 1 |
| Gray, R | 1 |
| Hoff, PM | 1 |
| Winn, R | 1 |
| Pazdur, R | 1 |
| Büchele, T | 1 |
| Grothey, A | 1 |
| Dempke, W | 1 |
| Bruey, JM | 1 |
| Paul, C | 1 |
| Fromentin, A | 1 |
| Hilpert, S | 1 |
| Arrigo, AP | 1 |
| Solary, E | 1 |
| Garrido, C | 1 |
| Manola, J | 1 |
| Valone, FH | 1 |
| Ryan, LM | 1 |
| Hines, JD | 1 |
| Wadler, S | 1 |
| Haller, DG | 1 |
| Arbuck, SG | 1 |
| Mayer, RJ | 1 |
| Thebo, JS | 1 |
| Senagore, AJ | 1 |
| Krygier, S | 1 |
| Luchtefeld, MA | 1 |
| Gnanasampanthan, G | 1 |
| Elsaleh, H | 1 |
| McCaul, K | 1 |
| Iacopetta, B | 1 |
| Köhne-Wömpner, CH | 1 |
| Fowler, WC | 1 |
| Eisenberg, BL | 1 |
| Hoffman, JP | 1 |
| Conti, JA | 1 |
| Seiter, K | 2 |
| Niedzwiecki, D | 2 |
| Botet, J | 1 |
| Martin, D | 2 |
| Costa, P | 2 |
| Wiseberg, J | 1 |
| McCulloch, W | 1 |
| Urmacher, C | 1 |
| Kurtz, RC | 1 |
| Murray, M | 1 |
| Cheson, BD | 1 |
| Windschitl, HE | 1 |
| O'Connell, MJ | 1 |
| Wieand, HS | 1 |
| Krook, JE | 1 |
| Rubin, J | 1 |
| Moertel, CG | 1 |
| Kugler, JW | 1 |
| Pfeifle, DM | 1 |
| Goldberg, RM | 1 |
| Laurie, JA | 1 |
| Paul, AR | 1 |
| Comis, RL | 1 |
| Schneider, A | 1 |
| Martin, DS | 1 |
| Colofiore, J | 1 |
| Sawyer, RC | 1 |
| Derby, S | 1 |
| Salvia, B | 1 |
11 reviews available for aspartic acid and Colorectal Neoplasms
| Article | Year |
|---|---|
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.
Topics: Amino Acid Sequence; Amino Acid Substitution; Antibodies, Monoclonal; Antibodies, Monoclonal, Humani | 2009 |
KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antibodies, Monoclonal; Antibodies, Monoclo | 2013 |
Preclinical and clinical aspects of biomodulation of 5-fluorouracil.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cisplatin; Colorectal Neopla | 1994 |
Biochemical modulation as an approach to reversal of antimetabolite resistance.
Topics: Antimetabolites, Antineoplastic; Aspartic Acid; Clinical Trials as Topic; Colorectal Neoplasms; Drug | 1994 |
Metastatic colorectal cancer: advances in biochemical modulation and new drug development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cisplatin; Colorectal Neoplasms; Diar | 1995 |
Recent advances in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Drug Administra | 1993 |
How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asp | 1995 |
The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Clin | 1996 |
Biomodulation of Fluorouracil in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Clin | 1998 |
Where do we stand with 5-fluorouracil?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Chro | 1999 |
Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cisp | 1992 |
9 trials available for aspartic acid and Colorectal Neoplasms
| Article | Year |
|---|---|
High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Di | 2003 |
A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Do | 2004 |
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chem | 1995 |
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Aspartic Acid; Colorectal Neoplasms; Drug Interactions | 1997 |
Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Fe | 1997 |
Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aspartic Aci | 1999 |
Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cance
Topics: Administration, Oral; Aged; Antineoplastic Agents; Aspartic Acid; Colorectal Neoplasms; Female; Fluo | 2001 |
A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA)
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Aspartic Acid; Colorectal Neoplasms; | 1991 |
A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer.
Topics: Adult; Aged; Aspartic Acid; Clinical Trials as Topic; Colorectal Neoplasms; Drug Evaluation; Drug Sy | 1990 |
28 other studies available for aspartic acid and Colorectal Neoplasms
| Article | Year |
|---|---|
Oncogenic KRAS creates an aspartate metabolism signature in colorectal cancer cells.
Topics: Argininosuccinate Synthase; Aspartic Acid; Carbon-Nitrogen Ligases with Glutamine as Amide-N-Donor; | 2021 |
[The frequency and spectrum of KRAS mutations in metastatic colorectal cancer].
Topics: Adult; Aged; Amino Acid Substitution; Aspartic Acid; Colorectal Neoplasms; Female; Glycine; Humans; | 2013 |
The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells.
Topics: Amino Acid Transport System X-AG; Antineoplastic Agents; Aspartic Acid; Camptothecin; Cell Death; Ce | 2015 |
SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
Topics: Adenoma; Adult; Aged; Animals; Aspartic Acid; Biomarkers, Tumor; Carcinoma; Cell Line, Tumor; Cell M | 2016 |
Association of MUTYH Gln324His and APEX1 Asp148Glu with colorectal cancer and smoking in a Japanese population.
Topics: Aged; Asian People; Aspartic Acid; Case-Control Studies; Colorectal Neoplasms; DNA Glycosylases; DNA | 2008 |
Amino acid Asp181 of 5'-flap endonuclease 1 is a useful target for chemotherapeutic development.
Topics: Aspartic Acid; Colorectal Neoplasms; DNA Repair; Enzyme Inhibitors; Flap Endonucleases; Humans; Mode | 2009 |
Predominance of G to A codon 12 mutation K-ras gene in Dukes' B colorectal cancer.
Topics: Adenine; Adenoma; Adult; Aged; Aged, 80 and over; Aspartic Acid; Carcinoma; Codon; Colorectal Neopla | 2012 |
A novel serum metabolomics-based diagnostic approach for colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Aspartic Acid; Biomarkers, Tumor; Case-Control Stu | 2012 |
Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2003 |
Multifocal inflammatory leukoencephalopathy: use of thallium-201 SPECT and proton MRS.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Aspartic Acid; Axons; Biopsy; Brain; Brain | 2003 |
Prevalence of the Y165C, G382D and 1395delGGA germline mutations of the MYH gene in Italian patients with adenomatous polyposis coli and colorectal adenomas.
Topics: Adenine; Adenoma; Adenomatous Polyposis Coli; Adult; Aged; Aspartic Acid; Case-Control Studies; Colo | 2004 |
Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk.
Topics: Adenomatous Polyposis Coli; Aspartic Acid; Base Pair Mismatch; Biomarkers, Tumor; Case-Control Studi | 2004 |
Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases.
Topics: Acetates; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; | 2006 |
NDR2 acts as the upstream kinase of ARK5 during insulin-like growth factor-1 signaling.
Topics: Amino Acid Sequence; Aspartic Acid; Calcium; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; | 2006 |
p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly-->Asp).
Topics: Adenocarcinoma; Amino Acid Sequence; Aspartic Acid; CD4-Positive T-Lymphocytes; CD8 Antigens; Cells, | 1994 |
5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic A | 1994 |
Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen.
Topics: Adenocarcinoma; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols | 1993 |
Distinct chromosomal alterations associated with TP53 status of LoVo cells under PALA selective pressure: a parallel with cytogenetic pathways of colorectal cancers.
Topics: Aspartic Acid; Chromosome Aberrations; Colorectal Neoplasms; Drug Resistance; Enzyme Inhibitors; Gen | 1999 |
Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Aspartic Acid; Co | 1999 |
Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Aspartic Acid; Biopolymers; Casp | 2000 |
K-ras mutational analysis of polyclonal colorectal cancers identifies uniclonal circulating tumor cells.
Topics: Aspartic Acid; Colorectal Neoplasms; Disease Progression; DNA Mutational Analysis; Genes, ras; Glyci | 2001 |
Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Aspartic Acid; Biomarkers, Tumor; Chemotherapy, Adjuva | 2001 |
Hepatic resection following systemic chemotherapy for metastatic colorectal carcinoma.
Topics: Aged; Antineoplastic Agents; Aspartic Acid; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; | 1992 |
Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1992 |
Clinical trials referral resource. Treatment of advanced colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Clinical Trial | 1991 |
Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspa | 1990 |
Biochemical modulation of 5-fluorouracil by PALA.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colo | 1990 |
Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid | 1989 |